The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
Open accessAbstract
The side effects of systemic chemotherapy used to treat cancer are often severe. For decades, oncologists have focused on treating the tumor, which may result in damage to the tumor‑bearing host and its immune system. Recently, much attention has been paid to the immune system of patients and its activation via biological therapies. Biological therapies, including immunotherapy and oncolytic virus (OV) therapy, are often more physiological and well tolerated. The present review elucidated how these therapies work and why these therapies may be better tolerated: i) In contrast to chemotherapy, immunotherapies induce a memory function of the adaptive immunity system; ii) immunotherapies aim to specifically activate the immune system against cancer; side effects are low due to immune tolerance mechanisms, which maintain the integrity of the body in the presence of B and T lymphocytes with their antigen‑receptor specificities and; iii) the type I interferon response, which is evoked by OVs, is an ancient innate immune defense system. Biological and physiological therapies, which support the immune system, may therefore benefit cancer treatment. The present review focused on immunotherapy, with the aim of reducing side effects and increasing long‑lasting efficacy in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 6×
“The side effects of these two approaches, however, were different: Grade 0-2 for the vaccination study compared with grade 1-4 for the ICB study.”
InfluentialIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Cellular and Molecular Immunology
Denman, A. M. (1992) · Postgraduate Medical Journal · doi:10.1136/pgmj.68.798.305 · Cited by 2,800
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“This is a long-lived T-cell population with enhanced capacity for self‑renewal (55).”
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · cited 1×
“However, the hallmarks of cancer are not only genetic (45) but are also epigenetic (46).”
HOW TCRS BIND MHCS, PEPTIDES, AND CORECEPTORS
Rudolph, M. G., Stanfield, R. L., & Wilson, I. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115658 · Cited by 1,310
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., & Ohtani, H. (1998) · PubMed · Cited by 1,193
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · cited 1×
“…APC in vivo are in fact normal ‘self’ peptides, with only a few from foreign antigens (29). ii) Lack of a costimulatory molecule of a tumor cell, expressing a tumor‑associated antigen (TAA), leads to a hyporesponsive state in a TAA‑specific responding T‑cell, which is known as T-cell anergy (30).”
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
T memory stem cells in health and disease
Gattinoni, L., Speiser, D. E., Lichterfeld, M., & Bonini, C. (2017) · Nature Medicine · doi:10.1038/nm.4241 · Cited by 620
Origin and differentiation of human memory CD8 T cells after vaccination
Akondy, R. S., Fitch, M., Edupuganti, S., Yang, S., Kissick, H. T., Li, K. W., Youngblood, B. A., Abdelsamed, H. A., McGuire, D. J., Cohen, K. W., et al. (2017) · Nature · doi:10.1038/nature24633 · Cited by 517
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 377
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
Bone marrow as a priming site for T-cell responses to blood-borne antigen
Feuerer, M., Beckhove, P., Garbi, N., Mahnke, Y., Limmer, A., Hommel, M., Hämmerling, G. J., Kyewski, B., Hamann, A., Umansky, V., et al. (2003) · Nature Medicine · doi:10.1038/nm914 · Cited by 353
Self-citationInterfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer
BÖHLE, A., & BRANDAU, S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000073852.24341.4a · Cited by 318
Luckey, C. J., Bhattacharya, D., Goldrath, A. W., Weissman, I. L., Benoist, C., & Mathis, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511137103 · Cited by 290
Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues
Delacher, M., Imbusch, C. D., Weichenhan, D., Breiling, A., Hotz-Wagenblatt, A., Träger, U., Hofer, A.-C., Kägebein, D., Wang, Q., Frauhammer, F., et al. (2017) · Nature Immunology · doi:10.1038/ni.3799 · Cited by 282
The bone marrow: a nest for migratory memory T cells
Di Rosa, F., & Pabst, R. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.04.011 · Cited by 273
Feuerer, M., Beckhove, P., Bai, L., Solomayer, E.-F., Bastert, G., Diel, I. J., Pedain, C., Oberniedermayr, M., Schirrmacher, V., & Umansky, V. (2001) · Nature Medicine · doi:10.1038/86523 · Cited by 263
Self-citationHan, S.-J., Glatman Zaretsky, A., Andrade-Oliveira, V., Collins, N., Dzutsev, A., Shaik, J., Morais da Fonseca, D., Harrison, O. J., Tamoutounour, S., Byrd, A. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.009 · Cited by 249
The Emperor of All Maladies: A Biography of Cancer
Mehta, P. (2011) · JAMA · doi:10.1001/jama.2011.798 · Cited by 225
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
Morgan, G., Ward, R., & Barton, M. (2004) · Clinical Oncology · doi:10.1016/j.clon.2004.06.007 · Cited by 221
CAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.128 · Cited by 220
Steiner, H. H., Bonsanto, M. M., Beckhove, P., Brysch, M., Geletneky, K., Ahmadi, R., Schuele-Freyer, R., Kremer, P., Ranaie, G., Matejic, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.038 · Cited by 216
Self-citationKumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 216
The Nature of the Intermolecular Forces Operative in Biological Processes
Pauling, L., & Delbrück, M. (1940) · Science · doi:10.1126/science.92.2378.77 · Cited by 211
Koks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N., & Van Gool, S. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 206
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_67 · Cited by 200
Durek, P., Nordström, K., Gasparoni, G., Salhab, A., Kressler, C., de Almeida, M., Bassler, K., Ulas, T., Schmidt, F., Xiong, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.022 · Cited by 196
Manz, B. N., Jackson, B. L., Petit, R. S., Dustin, M. L., & Groves, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018771108 · Cited by 191
Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation
TOUGH, D. F. (2004) · Leukemia & Lymphoma · doi:10.1080/1042819031000149368 · Cited by 189
Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase
Jarahian, M., Watzl, C., Fournier, P., Arnold, A., Djandji, D., Zahedi, S., Cerwenka, A., Paschen, A., Schirrmacher, V., & Momburg, F. (2009) · Journal of Virology · doi:10.1128/jvi.00211-09 · Cited by 177
Self-citationOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.035 · Cited by 177
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 150
RNA viruses as virotherapy agents
Russell, S. J. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700535 · Cited by 146
Lipponen, P., Eskelinen, M. J., Jauhiainen, K., Harju, E., & Terho, R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90579-5 · Cited by 139
Schulze, T., Kemmner, W., Weitz, J., Wernecke, K. ‐., Schirrmacher, V., & Schlag, P. M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0526-1 · Cited by 139
Self-citationHarrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 134
Yagawa, Y., Tanigawa, K., Kobayashi, Y., & Yamamoto, M. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.35 · Cited by 127
Ahlert, T., Sauerbrei, W., Bastert, G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1354 · Cited by 106
Heicappell, R., Schirrmacher, V., von Hoegen, P., Ahlert, T., & Appelhans, B. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910370416 · Cited by 106
Self-citationCancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Reid, E. G., Suneja, G., Ambinder, R. F., Ard, K. L., Baiocchi, R. A., Barta, S. K., Carchman, E. H., Cohen, A. L., Gupta, N. K., Johung, K. L., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0066 · Cited by 106
Khazaie, K., Prifti, S., Beckhove, P., Griesbach, A., Russell, S. J., Collins, M. K., & Schirrmacher, V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7430 · Cited by 102
Self-citationHow thymic antigen presenting cells sample the body's self-antigens
Derbinski, J., & Kyewski, B. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.08.003 · Cited by 99
Müller, M., Gounari, F., Prifti, S., Hacker, H. J., Schirrmacher, V., & Khazaie, K. (1998) · PubMed · Cited by 97
Self-citationFifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
Schirrmacher, V. (2016) · Biomedicines · doi:10.3390/biomedicines4030016 · Cited by 92
Self-citationSchirrmacher, V. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1088000 · Cited by 86
Self-citationVasaturo, A., Blasio, S. D., Peeters, D. G. A., de Koning, C. C. H., de Vries, I. J. M., Figdor, C. G., & Hato, S. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00417 · Cited by 85
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Niraula, S., Amir, E., Vera-Badillo, F., Šeruga, B., Ocaña, A., & Tannock, I. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8437 · Cited by 81
Collins, J. M., Redman, J. M., & Gulley, J. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506332 · Cited by 80
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity
Schirrmacher, V., Feuerer, M., Fournier, P., Ahlert, T., Umansky, V., & Beckhove, P. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.10.001 · Cited by 76
Self-citationWatanabe, D., & Goshima, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-7230-7_4 · Cited by 68
Sommerfeldt, N., Schütz, F., Sohn, C., Förster, J., Schirrmacher, V., & Beckhove, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4201 · Cited by 59
Self-citationAntiviral Response Dictated by Choreographed Cascade of Transcription Factors
Zaslavsky, E., Hershberg, U., Seto, J., Pham, A. M., Marquez, S., Duke, J. L., Wetmur, J. G., tenOever, B. R., Sealfon, S. C., & Kleinstein, S. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903453 · Cited by 57
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
Fournier, P., & Schirrmacher, V. (2012) · BioDrugs · doi:10.1007/s40259-012-0008-z · Cited by 57
Self-citationSampath, P., Li, J., Hou, W., Chen, H., Bartlett, D. L., & Thorne, S. H. (2012) · Molecular Therapy · doi:10.1038/mt.2012.257 · Cited by 53
IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity
Lattanzi, L., Rozera, C., Marescotti, D., D’Agostino, G., Santodonato, L., Cellini, S., Belardelli, F., Gavioli, R., & Ferrantini, M. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.10.003 · Cited by 49
Efficacy, safety, tolerability and price of newly approved drugs in solid tumors
Barnes, T. A., Amir, E., Templeton, A. J., Gomez-Garcia, S., Bravo, B. N., Šeruga, B., & Ocaña, A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.011 · Cited by 49
Ch’ng, W.-C., Stanbridge, E. J., Yusoff, K., & Shafee, N. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0095 · Cited by 43
Schirrmacher, V. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1222 · Cited by 42
Self-citationSchirrmacher, V., Fournier, P., & Schlag, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.854169 · Cited by 39
Self-citationRecurrent Glioblastoma Treated With Recombinant Poliovirus
Schneider, J. R., Patel, N. V., Kwan, K., & Boockvar, J. A. (2018) · Neurosurgery · doi:10.1093/neuros/nyy400 · Cited by 37
Schirrmacher, V., Haas, C., Bonifer, R., et al. (1997) · PubMed · Cited by 34
Self-citationSchirrmacher, V. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2213 · Cited by 30
Self-citationAllison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.08.047 · Cited by 24
αβ TCR-Mediated Recognition: Relevance to Tumor-Antigen Discovery and Cancer Immunotherapy
Reinherz, E. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0042 · Cited by 23
A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines
Tokuyasu, T. A., & Huang, J. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.52 · Cited by 11
Imaging of cytotoxic antiviral immunity while considering the 3R principle of animal research
Otto, L., Zelinskyy, G., Schuster, M., Dittmer, U., & Gunzer, M. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1628-7 · Cited by 10
Schirrmacher, V. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1530-2 · Cited by 9
Self-citation
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Silver nanoparticles: Synthesis, medical applications and biosafety
Xu, L., Wang, Y.-Y., Huang, J., Chen, C.-Y., Wang, Z.-X., & Xie, H. (2020) · Theranostics · doi:10.7150/thno.45413 · Cited by 1,315
Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization
Sanità, G., Carrese, B., & Lamberti, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587012 · Cited by 765
A systematic review and meta-analysis of psychological interventions to improve mental wellbeing
van Agteren, J., Iasiello, M., Lo, L., Bartholomaeus, J., Kopsaftis, Z., Carey, M., & Kyrios, M. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01093-w · Cited by 510
Metadata
- Authors
- Schirrmacher, V.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2018-12-10
- Volume
- 54
- Issue
- 2
- Pages
- 407-419
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2905111869
- Cited by
- 1,296
- References
- 91
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.